The Albanese Government is investing $10.3 million to tackle the most common cancer in our sunburnt country, skin cancer.
Regulatory
FDA Grants RMAT Designation to Novel TIL Therapy OBX-115 in Melanoma
This designation follows the fast track designation that was granted to OBX-115 for the same indication in July 2024.
FDA Grants Fast Track Designation to VMT01 for Unresectable/Metastatic MC1R+ Melanoma
The FDA has granted fast track designation to the development of the targeted alpha-particle therapy (212Pb) VMT01 for the diagnosis and treatment of patients with unresectable or metastatic melanoma, as well as those who have demonstrated melanocortin 1 receptor (MC1R) expression, Perspective Therapeutics announced in a news release.
VMT01 Earns FDA Fast Track Designation in MC1R-Positive Melanoma
The novel agent VMT01 is designed to target and deliver 212Pb to MC1R-expressing tumors like metastatic melanoma.